Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

NCT07271121 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin Lymphoma Refractory/ Relapsed

Interventions

OTHER: MB-CART-19.1

Sponsor

King Hussein Cancer Center